| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $219,806 | 8 | 100 |
Sells | $0 | 0 | 0 |
| FROST PHILLIP MD ET AL | 8 | $219,806 | 0 | $0 | $219,806 |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Over the last 12 months, insiders at Cocrystal Pharma, Inc. have bought $219,806 and sold $0 worth of Cocrystal Pharma, Inc. stock.
On average, over the past 5 years, insiders at Cocrystal Pharma, Inc. have bought $753,642 and sold $1.7M worth of stock each year.
Highest buying activity among insiders over the last 12 months: FROST PHILLIP MD ET AL () — $219,806.
The last purchase of 20,000 shares for transaction amount of $19,952 was made by FROST PHILLIP MD ET AL () on 2026‑02‑24.
| 2026-02-24 | FROST PHILLIP MD ET AL | 20,000 0.1966% | $1.00 | $19,952 | +4.52% | |||
| 2026-02-06 | FROST PHILLIP MD ET AL | 50,000 0.4756% | $0.95 | $47,280 | +4.13% | |||
| 2025-12-31 | FROST PHILLIP MD ET AL | 50,000 0.4862% | $0.95 | $47,275 | +4.70% | |||
| 2025-12-30 | FROST PHILLIP MD ET AL | 20,000 0.1986% | $0.97 | $19,310 | +7.52% | |||
| 2025-12-26 | FROST PHILLIP MD ET AL | 40,000 0.3907% | $0.97 | $38,944 | +4.88% | |||
| 2025-12-24 | FROST PHILLIP MD ET AL | 25,000 0.243% | $0.97 | $24,258 | +4.20% | |||
| 2025-11-26 | FROST PHILLIP MD ET AL | 4,000 0.0384% | $0.99 | $3,975 | +0.99% | |||
| 2025-11-25 | FROST PHILLIP MD ET AL | 20,000 0.2037% | $0.94 | $18,812 | +8.31% | |||
| 2023-04-04 | FROST PHILLIP MD ET AL | 1.02M 11.981% | $1.97 | $2M | -5.85% | |||
| 2021-08-20 | PFENNIGER RICHARD C JR | director | 40,000 0.0414% | $1.03 | $41,120 | -46.08% | ||
| 2021-05-04 | Sale | Schinazi Raymond F | 10 percent owner | 575,000 0.9104% | $2.95 | $1.7M | -56.54% | |
| 2019-10-25 | Schinazi Raymond F | 10 percent owner | 7,906 0.0202% | $1.15 | $9,092 | -14.81% | ||
| 2019-10-24 | Schinazi Raymond F | 10 percent owner | 5,094 0.0122% | $1.15 | $5,858 | -20.00% | ||
| 2019-10-23 | Schinazi Raymond F | 10 percent owner | 3,935 0.0085% | $1.04 | $4,087 | -20.00% | ||
| 2016-12-23 | Sale | Lee Sam | 2.2M 0.343% | $0.44 | $968,000 | -37.50% | ||
| 2016-09-01 | WILCOX GARY | 10,000 0.0015% | $0.41 | $4,100 | -30.00% | |||
| 2016-09-01 | Schinazi Raymond F | 4.88M 0.7103% | $0.41 | $2M | -30.00% | |||
| 2016-09-01 | BLOCK DAVID S | 10,000 0.0015% | $0.41 | $4,100 | -30.00% | |||
| 2016-03-15 | Schinazi Raymond F | 2.94M 0.3532% | $0.51 | $1.5M | -22.95% | |||
| 2016-03-15 | FROST PHILLIP MD ET AL | 2.94M 0.3532% | $0.51 | $1.5M | -22.95% |
| FROST PHILLIP MD ET AL | 1908551 18.621% | $2.03M | 14 | 0 | <0.0001% | |
| WILCOX GARY | 16948605 165.3609% | $18.05M | 3 | 0 | ||
| Lee Sam | 13087847 127.693% | $13.94M | 0 | 1 | ||
| Schinazi Raymond F | 10 percent owner | 7674960 74.8816% | $8.17M | 6 | 1 | <0.0001% |
| HSIAO JANE PH D | 3435294 33.5168% | $3.66M | 2 | 0 | ||
| Rubin Steven D | 733484 7.1563% | $781,160.46 | 2 | 0 | ||
| Meckler Jeffrey A | 657161 6.4117% | $699,876.47 | 4 | 0 | ||
| BLOCK DAVID S | 168696 1.6459% | $179,661.24 | 3 | 0 | ||
| PFENNIGER RICHARD C JR | director | 40000 0.3903% | $42,600.00 | 1 | 0 | <0.0001% |
$17,168,388 | 54 | -43.55% | $10.66M | |
$1,616,354 | 20 | -12.22% | $12.1M | |
$114,619,342 | 20 | -7.41% | $15.22M | |
$6,733,543 | 17 | -19.02% | $9.73M | |
$49,590 | 16 | -37.31% | $13.24M | |
$25,487,383 | 15 | -4.37% | $13.87M | |
$79,536,861 | 15 | -6.81% | $10.08M | |
$20,759,738 | 11 | -44.68% | $10.03M | |
$4,146,041 | 11 | -40.86% | $12.19M | |
$11,777,042 | 10 | -11.94% | $10.4M | |
$241,042 | 9 | -11.02% | $9.74M | |
$90,087 | 9 | 20.06% | $9.11M | |
$206,317 | 7 | -29.23% | $14.07M | |
Cocrystal Pharma, Inc. (COCP) | $2,060,158 | 5 | -21.35% | $10.92M |
$149,996 | 5 | 16.26% | $9.61M | |
$9,828 | 3 | -32.17% | $13.07M | |
$157,740 | 3 | 153.95% | $8.9M | |
$14,530 | 3 | 62.23% | $12.41M | |
$500,000 | 1 | -22.94% | $14.19M |
| Increased Positions | 10 | +34.48% | 128,630 | +19.34% |
| Decreased Positions | 10 | -34.48% | 23,081 | -3.47% |
| New Positions | 7 | New | 117,054 | New |
| Sold Out Positions | <1 | Sold Out | 16 | Sold Out |
| Total Postitions | 29 | 0% | 770,583 | +15.87% |
| Vanguard Group Inc | $266.00 | 1.92% | 268,080 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $127.00 | 0.91% | 127,928 | +2,900 | +2.32% | 2025-09-30 |
| Geode Capital Management, Llc | $73.00 | 0.53% | 73,929 | +829 | +1.13% | 2025-09-30 |
| Blackrock, Inc. | $73.00 | 0.53% | 73,746 | 0 | 0% | 2025-09-30 |
| Neuberger Berman Group Llc | $32.00 | 0.23% | 31,886 | +31,886 | New | 2025-09-30 |
| Jane Street Group, Llc | $21.00 | 0.15% | 21,044 | +21,044 | New | 2025-09-30 |
| State Street Corp | $20.00 | 0.15% | 20,543 | 0 | 0% | 2025-09-30 |
| Parallel Advisors, Llc | $13.00 | 0.09% | 12,611 | -2,617 | -17.18% | 2025-09-30 |
| Northern Trust Corp | $12.00 | 0.09% | 11,921 | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $9.00 | 0.07% | 9,092 | -9 | -0.1% | 2025-09-30 |